Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'

Scand J Infect Dis. 2010 Mar;42(3):231-3. doi: 10.3109/00365540903443157.

Abstract

Metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa) is a cause of life-threatening infections. With parenteral colistin not available in Japan, we treated MDR P. aeruginosa sepsis with monobactam and aminoglycoside combination therapy, with screening using a 'break-point checkerboard plate'.

Publication types

  • Case Reports

MeSH terms

  • Aminoglycosides / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Drug Resistance, Multiple, Bacterial*
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Japan
  • Male
  • Microbial Sensitivity Tests / methods
  • Middle Aged
  • Monobactams / therapeutic use*
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification
  • Sepsis / drug therapy
  • Sepsis / microbiology
  • Treatment Outcome
  • beta-Lactamases / biosynthesis*

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Monobactams
  • beta-Lactamases